Suven Life Sciences Ltd has obtained two product patents from New Zealand for its new chemical entities (NCEs) related to the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company, a release issued on Friday said.
They were being developed as therapeutic agents and were useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinsons and schizophrenia.